GANT 58 is an inhibitor of GLI1-induced transcription. This affects the functional aspects of cell growth, differentiation and activation. The modulatory ability of this drug is critical to maintenance of self-tolerance, immune suppression and tumor immunosurvelliance involved in T regulatory cells. GANT58 also inihibits hedgehog signalling inducing apoptosis in acute T cell leukemia cells.
gant 58 is an antagonist of gli that inhibits gli1-induced transcription with an ic50 value of 5 μm [1].gli1 is a human glioblastoma isolated protein which belongs to gli protein family. gli proteins act as effectors in hedgehog signaling pathway and get involved in cell proliferation, determination and patterning during embryo development.gant 58 is considered to inhibit gli1-mediated gene trans-activation with a high selectivity for hedgehog signaling pathway. when tnf signaling/nfkb activation, glucocorticoid, receptor gene transactivation, and the ras-raf-mek-mapk cascade were treated with gant 58, no inhibition was observed. when sag-treated shh-l2 cells were treated with 10 μm gant 58 for 48 hr, the reduction of hedgehog pathway signaling was observed, whereas gli1 mrna level reduction was induced by the treatment of 10 μm gant 58 for 2-3 days. indeed, gant 58 was confirmed as inhibitor of hedgehog signaling pathway downstream sufu and smo [1]. furthermore, gant 58 treatments for 48 hr resulted in the significant reduction of cell viability in a dose-dependent manner for ccrfecem, cem7e14, cem1e15 and jurkat cells. when ccrfecem cells were treated with 10 μm gant 58 for 48 hr, the percentage of cells in g1/s phase increased whereas the percentage in g2/m phase decreased [2].in mouse model with xenograft, daily s.c. injection of gant 58 resulted in significant suppression of tumor cell growth. 50 mg/kg/d gant 58 injections for 18 days induced the suppression of additional xenograft growth and restrict the increase of tumor size. no side effects were observed during the treatment [1].
